Mountain View, CA – Cordance Medical, a leader in non-invasive medical technologies for brain disease treatment, proudly announces that the European Patent Office intends to grant its cornerstone patent “Ultrasound Guided Opening of the Blood-Brain Barrier.”
This innovative patent centers on a non-invasive technique to precisely guide low-frequency ultrasound through the skull to a physician-defined region of interest within the brain. Unlike existing technologies requiring costly and invasive solutions, this technology utilizes the patient’s own anatomy to enable real-time targeting. This breakthrough eliminates the need for immobilization or tethering during treatment, setting a new standard in patient comfort and accessibility.
Dr. Bhaskar Ramamurthy, CEO of Cordance Medical, commented, “This patent represents a significant milestone for Cordance Medical and the future of brain disease treatment. By combining precision, non-invasiveness, and real-time adaptability, this technology has the potential to transform how we safely and effectively target the blood-brain barrier. We are excited to bring this revolutionary technology closer to patients.
About Cordance Medical
Cordance Medical is a pioneering medical technology company focused on developing non-invasive tools to improve treatment outcomes for patients with brain diseases, including brain cancers, Alzheimer’s, and Parkinson’s. Cordance’s flagship NeuroAccess™ platform is designed to safely and temporarily open the blood-brain barrier, enabling better drug delivery and advancing liquid biopsy techniques for the real-time monitoring of brain disease. For more information, please visit www.cordancemedical.com.